1 © 2008 Emmett Keeler RAND More realistic Life Exp. calculations Deale Gompertz law, New Deale Malin Breast Cancer Paper.

Slides:



Advertisements
Similar presentations
Comparing Two Proportions (p1 vs. p2)
Advertisements

1 Case-Control Study Design Two groups are selected, one of people with the disease (cases), and the other of people with the same general characteristics.
Breast Cancer Reimbursement Policy in Taiwan Mao-Ting Sheen Director Bureau of National Health Insurance Department of Health, Executive Yuan November.
Extension Article by Dr Tim Kenny
MS&E 220 Project Yuan Xiang Chew, Elizabeth A Hastings, Morris Jinhui Zhang Probabilistic Analysis of Cervical Cancer Screening and Vaccination.
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
Main Points to be Covered
Risk and Relative Risk. Suppose a news article claimed that drinking coffee doubled your risk of developing a certain disease. Assume the statistic was.
The Tools of Demography and Population Dynamics
Samuel Clark Department of Sociology, University of Washington Institute of Behavioral Science, University of Colorado at Boulder Agincourt Health and.
Vanderbilt Sports Medicine Chapter 4: Prognosis Presented by: Laurie Huston and Kurt Spindler Evidence-Based Medicine How to Practice and Teach EBM.
Breast Cancer Awareness 1 Breast Cancer Awareness Workshop Sponsored by Y-ME.
Screening for Lung Cancer Jess Dalehite, M.D. Southwest Medical Imaging Midland Memorial Hospital.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Measuring Epidemiologic Outcomes
Analysis of Complex Survey Data
Kayla Potts Amber Presley J. Llanelly Paz Whitney Chislom “When Life Kicks You… Let It Kick You Forward! We Got Your BACK.” - Kay Yow.
Methods - Rehearsel Nico Keilman Demography of developing countries ECON 3710 I-lands demografi ECON 3720 January 2009.
The Cancer Pedigree BRCA What?. Outline Introduction: Understanding the weight of genetics in Ovarian Breast Cancer BRCA 1 and BRCA 2 Genes – Function.
Breast Cancer In Palestine Belal M. Abu Samha. Introduction Breast cancer is a cancer that starts in the cells of the breast in women and men. Worldwide,
Lecture 3: Measuring the Occurrence of Disease
Multiple Choice Questions for discussion
These slides were released by the speaker for internal use by Novartis.
Finding N.E.M.O. Marvin R. Balaan, MD, FCCP System Division Director, Division of Pulmonary and Critical Care Medicine Allegheny Health Network, Pittsburgh.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
Summary of measures of population Health Farid Najafi MD PhD School of Population Health Kermanshah University of Medical Sciences.
EPIB-591 Screening Jean-François Boivin 29 September
Biostatistics Case Studies 2005 Peter D. Christenson Biostatistician Session 4: Taking Risks and Playing the Odds: OR vs.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
Population Projections: Social Security Administration Alice Wade, Office of the Chief Actuary Population Projections: Social Security Administration Alice.
Measuring Health Outcomes
Breast Cancer Care of Mexican American Women in High Poverty California Neighborhoods: Protective Effects of Social and Financial Capital, Including Health.
Evidence Based For invasive breast cancer BCT is Tumor excision, axillary node dissection, whole breast radiation Modified mastectomy is total mastectomy.
March 10, 2014 NURS 330 Human Reproductive Health.
01/20151 EPI 5344: Survival Analysis in Epidemiology Epi Methods: why does ID involve person-time? March 10, 2015 Dr. N. Birkett, School of Epidemiology,
01/20141 EPI 5344: Survival Analysis in Epidemiology Epi Methods: why does ID involve person-time? March 13, 2014 Dr. N. Birkett, Department of Epidemiology.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year.
{ Challenges in cost-utility analysis in the critical care setting Ville Pettilä MD, PhD, A/P Helsinki University Hospital VP SFAI- veckan.
Measures of Association and Impact Michael O’Reilly, MD, MPH FETP Thailand Introductory Course.
Human Population as an Environmental Problem Ultimately the greatest environmental threat that mankind has created. Two factors contribute together: 1)The.
Screening and its Useful Tools Thomas Songer, PhD Basic Epidemiology South Asian Cardiovascular Research Methodology Workshop.
“Big Data, Better Treatment”: The work of the Early Breast Cancer Trialists’ Collaborative Group Rory Collins BHF Professor of Medicine & Epidemiology.
1 © 2008 Emmett Keeler RAND When to do a Diagnostic Test Expected Value of Information Triage to testing Tree flipping and strategic form of trees.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
01/20151 EPI 5344: Survival Analysis in Epidemiology Actuarial and Kaplan-Meier methods February 24, 2015 Dr. N. Birkett, School of Epidemiology, Public.
Biostatistics Case Studies 2014 Youngju Pak Biostatistician Session 5: Survival Analysis Fundamentals.
Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 2: Aging and Survival.
01/20151 EPI 5344: Survival Analysis in Epidemiology Hazard March 3, 2015 Dr. N. Birkett, School of Epidemiology, Public Health & Preventive Medicine,
02/20161 EPI 5344: Survival Analysis in Epidemiology Hazard March 8, 2016 Dr. N. Birkett, School of Epidemiology, Public Health & Preventive Medicine,
Or you can use crude data. Crude birth rate is the number of childbirths per 1,000 people per year (in estimation)…and crude death rates, similarly, are.
CT Screening for Lung Cancer vs. Smoking Cessation: A Cost-Effectiveness Analysis Pamela M. McMahon, PhD; Chung Yin Kong, PhD; Bruce E. Johnson; Milton.
Advancing Health Economics, Services, Policy and Ethics Stuart Peacock Cancer Control Research, BC Cancer Agency Canadian Centre for Applied Research in.
Quality & Sustainability in Cancer Control: A System Performance Spotlight Report To use a hyperlink, right click on it and select ‘Open Hyperlink’, or.
Date of download: 5/31/2016 From: Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 Years: A Comparative Modeling.
Review Design of experiments, histograms, average and standard deviation, normal approximation, measurement error, and probability.
Chapter 15 (not 15.8) Selected Chapter questions: 1,5,6 1.
BREAST SELF- AWARENESS FOR OUR COMMUNITY Updated 3/2015.
Date of download: 7/6/2016 From: Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies: Model Estimates.
Cancer screening and cancer diagnosis. All medical advice is that the earlier you discover a cancer the greater your odds are of beating it. In part this.
The University of Sheffield Extrapolation methods:
Benjamin Kearns, The University of Sheffield
Mammograms and Breast Exams: When to start /stop mammograms
For a copy of the poster:
A Few Facts About Breast Cancer
Value of Pharmaceuticals in Managed Care Pharmacy
NAPLEX preparation: Biostatistics
Value of Pharmaceuticals in Managed Care Pharmacy
Summary measures of mortality – Life expectancy and life tables
Breast Cancer.
Chapter 4 SURVIVAL AND LIFE TABLES
Presentation transcript:

1 © 2008 Emmett Keeler RAND More realistic Life Exp. calculations Deale Gompertz law, New Deale Malin Breast Cancer Paper

2 © 2008 Emmett Keeler RAND Key Points DEALE is easy to use, but not very accurate Life tables are the gold standard for calculating the impact of varied additive hazards on discounted LE, But Mixed DEALEs work well In Malin, CEA is used to devise a low cost breast cancer package for uninsured women-- shows tradeoffs between covering more people and generosity of care.

Survival and Life Expectancy (LE) Let S(t) = number alive at start of year t, s(t) = survival rate from year t to t+1, so S(t+1) = s(t)S(t). What is S(t) - S(t+1)? Life Expectancy = Average years to be lived = (∑ S(t)) / S(0). “age” at death for those dying S(t) S(t+1) Number surviving, S(t) Years from start Start t t+1 S(0) another year for survivors 1000? area under survival curve

Life Expectancy (LE) with continuous death Let S(t) = number alive at time t, and dS/dt = -h(t)S(t). h(t) is called the hazard of dying. S(t) = S(0) exp (∫-h(x)dx) Life Expectancy = Average years lived = (∫S(t)) / S(0). If h(t) = h, LE = 1/h S(t) Number surviving, S(t) Years from start Start t S(0) more years for survivors

Life Tables for males, US 2004 Age death rate in interval number living at start deaths in interval years lived in interval years lived in this and all future intervals life expect at start , , ??

6 © 2008 Emmett Keeler RAND Captions for Life Table Excerpt from Notes: Number dying = Death rate x number living at start of interval Years lived in interval includes partial years for those dying 74,171/993 = 74.7 gives LE at age 1. Years lived in last age bin (here 100+) = number at start x LE (100) Period LE is a synthetic measure of current population health based on 2004 death rates  Not how long a baby born in 2004 will live. Cohort LE is a measure of how long a certain cohort of people lived. Cancer trials collect this.

Prob of Survival 1.0 Time from Beginning of intervention Area under curve = Life Expectancy after intervention If we divide S(t) by the number treated then S(0) = 1, S(t) is a probability, and LE = area under survival curve/1. Cohort Life Expectancy after treatment

DEALE: If death rate is constant d, Life Expectancy = 1/d Here death rate =. 25, so LE = 4 years. For proof see next slide. Note L=1/d d= 1/L

9 © 2008 Emmett Keeler RAND Derivation of DEALE equation Calculus version: survival S(t) = exp(-dt), for hazard of dying d LE = area under survival curve = ∫ exp(-dt)dt = -1/d * exp(-dt) | when t = ∞ - when t = 0 = -1/d [0 - 1] = 1/d LE = 1 + s +s 2 + s 3 + …s n sLE = s +s 2 + s 3 + …s n + s n+1 LE - sLE = 1 - s n+1 ~1 for large n LE = ∑s i = 1/(1-s) = 1/d for large n

10 © 2008 Emmett Keeler RAND Discounting is like death Discounting future years at rate r% is formally like assuming r% additional deaths each year. At the start of the second year, we have a proportion d who have died. When we add in years from year 2 in total years lived, each year has value 1-r So these years = S 0 (1-d)(1-r) = S 0 (1-d-r+dr)  dr is the product of two small #s and so negligible  If we divide year into smaller time periods, dr disappears.  in the third year we have S 0 (1-d 0 -r)(1-d 1 -r) disc. years etc. So discounted LE = ∑(1-d-r) n if death rate is constant

11 © 2008 Emmett Keeler RAND Example: Using the DEALE to calculate discounted life expectancy Assume a 50 year old white woman will have the average 2005 US LE of 33.3 years after cure. Assume a discount rate of 5%. What is her discounted life expectancy? Death rate = 1/33.3 =.03. So d+r =.08, so discounted life expectancy = 1/.08 = What if we assume she will never die, I.e. L = ∞. What is her discounted LE?

12 © 2008 Emmett Keeler RAND Mortality and age But, overall death rates increases steadily with age (Gompertz,1826).  Death rate doubles every 8.5 years ;  women’s rate = 60% that of men the same age  similarly for incidence of heart disease So, crude death rate is smaller than 1/L  Especially in countries with young populations.  crude rate a poor measure of current health

13 © 2008 Emmett Keeler RAND What is impact of added hazards on LE? Need some model to fit data, and then to do calculations. We often assume a baseline or “normal” death rate and model death from additional risks as added to that.  So if the death rate from disease B is b, then the death rate for a 40 year old with B is modeled as d 40 +b. This ignores the fact that d 40 includes some b.  b may change predictably in years from incidence.

14 © 2008 Emmett Keeler RAND Using the DEALE to calculate impact of dread disease Consider a 50 year old white woman with the average US 2005 LE of years. She gets breast cancer and after treatment is assumed to have a 7% chance of dying from it each year. Assume hazard of “normal” and breast cancer deaths add. “Normal” death hazard = 1/33.33 =.03. Combined hazard = = 0.1, so new life expectancy is 1/.01 = 10 years. What is her Discounted LE, with a 5% discount rate?

15 © 2008 Emmett Keeler RAND Effect of added hazard in Fixed Lifetime LE model Assume without disease, death rate is 0 for L years, and then the person dies.  what does the survival curve look like? What if there is an added hazard of 5% per year? Staircase: new LE = 1+s+s 2 +…s L-1 = (1-s L )/(1-s) = 16.4  half-cycle correction 16.4(1-d/2) = Or new Life expect. = ∫ 0 to L : exp(-.0513t)dt = [1-exp(-.0513L)]/ If L = 33.3, this is 15.96

16 © 2008 Emmett Keeler RAND A better formula for LE with dread disease Weighted average of DEALE and Fixed Lifetime model of LE Suppose in someone over 50, normal LE = L, hazard from dread disease = d LE = p(1- exp(-dL))/d +(1-p)/(d + 1/L), with p =.5 to.75 works well over a wide range of d and L.  Easier to implement in EXCEL than a life table.  for the 50 year old woman, with p =.75 L =33.3, d =.05, we have LE =.75 * * 12.5 = 15.1 Keeler E, Bell R. New Deales: other approximations of Life Expectancy, Med Dec Making (12) ,1992.

17 © 2008 Emmett Keeler RAND Malin paper Context In 1999, California paid for mammographic screening of uninsured women, but not subsequent treatment. California was considering giving up to $15 million for their treatment. Wanted advice on what to cover. I helped Jennifer Malin with quick project.

18 © 2008 Emmett Keeler RAND Framing Use cost-effectiveness analysis to rate different treatments -- costs from CA government perspective = direct medical, but health benefits to women. For budget, need estimates of “incidence.”  actual: cases expected from current screening levels  potential: if screens = uninsured x incident cancer <65 Early (curable) breast cancer in women under 65. Studied 8 representative women.  45 or 60  ER+ (can use tamoxifen) or ER-  lymph node involved (40%) or not (20% 10 year survival)

19 © 2008 Emmett Keeler RAND Treatments Diagnostic evaluation always given Therapy for DCIS always given Surgery: mastectomy or BCS  post-op radiation  Adjuvant therapy tamoxifen for ER+ and chemo  reconstruction after mastectomy  BMT: expensive risky last chance procedure Follow-up: regular always given  intensive shown to have no benefit in trials

20 © 2008 Emmett Keeler RAND Data on benefits and costs EBCTCG had great data on treatment of early breast cancer: surgery, radiation and chemo. We also looked at reconstruction and BMT where data was not as good. Had expert opinion from earlier papers. Costs from Medicare allowed charges for services, AWP for drugs (with PHS discounts in sens. analysis)

21 © 2008 Emmett Keeler RAND Issues Utility of life during and after treatment  disutility of treatment x length of treatment?  later life disutility? Evidence vs. Standard of care  radiation after surgery does not improve survival BCS dominates mastectomy + reconstruction.  if it is possible.  but law mandates private insurers cover reconstruction No evidence on BMT effectiveness  we calculated how good it would have to be to be cost- effective.

22 © 2008 Emmett Keeler RAND Calculating Life expectancy gains Studied 8 types of women  age 45, 60  node - and + = 20, 40% 10 year survival,  ER+ (can use tamoxifen), ER- breast cancer. Used reported odds from EBCTCG for survival to 10 years, then constant added BC risk over normal women for rest of life.  constant added hazard fit well for first 10 years Lots of calculations to get discounted LE, so used mixed Deale, EXCEL  Validated results against Life Tables for one treatment always within.03 years.

23 © 2008 Emmett Keeler RAND Life tables for women with breast cancer Start with standard life table for population of interest Add in another column for hazard of dying if you have breast cancer by age  this column depends on age of onset  type of disease and treatment Use combined hazard = sum of these columns

24 © 2008 Emmett Keeler RAND Presenting Results For all recommendations, we talked about number of lives saved, not QALYs gained. Put together a minimum package of very cost- effective treatments Costed some more expensive treatments: more radiation, breast reconstruction Compared this to giving the minimum package to more uninsured women with cancer.